Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
Hi, everyone. I'm Arsalan Arif, the publisher of Endpoints News, and I'm pleased to be your moderator today. Today's webinar is sponsored by Agilex Biolabs in Australia. Our topic is Why Australia is the World's Leading Early Phase Destination - Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs. I'm joined by two great guests today. Kurt Sales, the Director of Immunoassay at Agilex Biolabs, and Jane Kelly, the CEO of CMAX Clinical Research.